Small Cap Feast

24th April 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 



Delistings: 








Whats baking in the oven?

Potential Initial Public Offerings:


Reverse Takeovers:

16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radical Limited for a consideration of approximately £1.3m, payable by the issue of new ordinary shares in Electric Guitar. The Acquisition constitutes a reverse takeover under the Listing Rules and therefore shareholder approval for the Acquisition is being sought at a general meeting of Electric Guitar to be convened for 1 May 2024.

17 April 2024: TGI Fridays, Inc. (TGIF) Hostmore plc announces that it has reached agreement on a non-binding basis for a proposed all-share acquisition of TGI Fridays, Inc. The Proposed Transaction would result in existing Hostmore shareholders holding 36% of the enlarged business upon completion (the Combined Group), with TGI Fridays shareholders holding a 64% shareholding. TGI Fridays is expected to be purchased for an enterprise value of £177m, or approximately 5.4x its FY23 underlying EBITDA. The Combined Group is expected to be renamed TGI Fridays plc, with its shares admitted to trading on the LSE’s Main Market. Completion of the Proposed Transaction expected to be by the end of Q3 2024.


Change of Market:

8 April 2024: (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated proposition as a value alternative to full price specialist retailers. The Company is listed on the premium segment of the Main market of the London Stock Exchange. The Company has announced its intention to change to the AIM market on the 3 May 2024.

Dual Listing :

23 April 2024: Wellnex Life Limited (ASX:WNX), an Australian consumer healthcare company, has commenced the process to dual list on the London Stock Exchange. The Company believes that a dual listing will increase its international profile, particularly in Europe where Wellnex has an existing supply agreement with Haleon into the UK. Currently, the market capitalisation of Wellnex is AUD$23.8m.


Banquet Buffet

1Spatial plc 59.5p £66.0m (SPA.L)
The global company offering Location Master Data Management (LMDM) software and solutions, announces the audited results for the year ended 31 January 2024 (FY24). Revenue increased 8% to £32.3m, resulting in an increase of 15% in gross profit. Recurring revenue accounts for 56% of total revenues (FY23: 49%). Net cash was £1.1m (£1.1m at the end of FY23). There has been a solid start to trading in the current financial year with a growing pipeline and two significant framework agreements secured, with the State of Texas and UK Cabinet Office. The Board remains confident in delivering further progress in FY25 with a further growth step up in FY26.

ActiveOps plc 105p £74.9m (AOM.L)
The provider of Decision Intelligence software for service operations, provides a trading update for the year ended 31 March 2024. Revenue is expected to be approximately £26.8m, up 5% (FY23: £25.5m). Adjusted EBITDA is expected to be at least £2.2m (FY23: £0.7m), including an increase in capitalised R&D of approximately £0.5m to £1.35m (FY 2023 £0.85m, capitalised). Year-end cash position was £17.6m (FY23: £15.4m). The Company looks forward to the year ahead with confidence.

Angle PLC 15p £39.1m (AGL.L)
The liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, has signed a supplier agreement with AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response (DDR) assay for the detection of micronuclei in CTCs as a measure of DDR. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.

Filtronic plc 52p £112.9m (FTC.L)
The designer and manufacturer of products for the aerospace, defence, telecoms infrastructure and low earth orbit (LEO) space markets, announces that the Company has been successful in executing these contracts over the last six months and as such FY2024 revenue will now be marginally ahead of expectations and EBITDA will be significantly ahead of expectations. These recent contract wins provides visibility over the medium term. As a result, the FY25 outlook is significantly ahead of current market expectations for both revenue and EBITDA.

Gear4music 145p £30.4m (G4M.L)
The largest UK based online retailer of musical instruments and music equipment, announces a trading update for the year ended 31 March 2024 (FY24). Total revenue was £144.4m, down 4% from £152.0m in FY23. EBITDA is expected to be in line with market expectations. Net debt was reduced significantly to £7.3m (31 March 2023: £14.5m), ahead of market expectations. The Board is confident that the positive impact of the cost reductions made during FY24 will deliver full-year benefits in FY25.

MYCELX Technologies 56p £12.9m (MYX.L)
The clean water and clean air technology company provides a update on its recent business development. The Company has completed a treatability study paving the way for inclusion in a multiple technology, four-month pilot trial treating PFAS (Perfluoroalkyl and Polyfluoroalkyl Substances) contamination at a municipal wastewater treatment facility. The trial is expected to commence in Q1 2025, and the final outcome of the trial is expected to determine the award of a contract by the municipality in 2025..

Sound Energy 0.825p £16.4m (SOU.L)
The transition energy company announces its audited results for the year ended 31 December 2023. Gross profit was £42k (FY22: £5.7m due to reversal of impairment of development assets and exploration costs by £5.7m). Loss for the year was £7.2m. Cash and short-term deposits at the period end were £3.0m (£3.9m as at 31 December 2022). Loans and borrowings totalled £33.3m (£29.1m as at 31 December 2022). Phase 1 Micro LNG project: Initial well works setting packers in each well was completed in Q4 2023 with rig activities scheduled for June 2024. Processed gas is expected at plant by end 2024 with LNG sales thereafter.

Star Energy Group 11.4p £14.7m (STAR.L)
The British energy company announces its results for the year ended 31 December 2023. Revenue was £49.5m, down 16% from £59.2m in 2022. Adjusted EBITDA was £16.1m, down 24% from £21.1m in 2022. Net debt was £1.6m, compared to £6.1m at the end of 2022. Net production for the period averaged 2,100 boepd (2022: 1,898 boepd). The net production is anticipated to be c.2,000 boepd in 2024, with operating costs of c.$41/boe (assuming an average exchange rate of £1:$1.26). The Company expects a cash capex of £5.5m in 2024 for near-term incremental projects with short cycle returns, maintenance and optimisation of existing oil and gas sites.

SRT Marine Systems 22.5p £50.1m (SRT.L)
The global company which develops and provides integrated maritime surveillance, monitoring, management and safety systems, notes the recent share price movement and reporting in the Philippine press with regard to the IMEMS fisheries project. SRT wishes to clarify that the IMEMS contract was won following a competitive international tender, which has been successfully implemented and is operational. On Monday the Ombudsman confirmed that both SRT and Richard Hurd are cleared, but has recommended further investigation into Simon Tucker and other individuals outside of SRT. The Board is fully supportive of Simon who is now working to clear his name. Trading remains in line with market expectations.

Supreme plc 125p £145.6m (SUP.L)
The manufacturer, supplier, and brand owner of fast-moving consumer goods, provides a trading update for the year ended 31 March 2024 (FY24). FY24 revenue is expected to be around £225.0m, up 45% (FY23: £155.6m) and Adjusted EBITDA of at least £38.0m (FY23: £19.4m), in-line with current market expectations. Supreme's continued investment in rechargeable pod system vaping devices, coupled with its long-standing progress in developing a uniquely diverse vape product mix, ensures that it is well positioned to adapt to changes in the UK e-cigarette market.

24 April 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram